



## International Symposium on Radiopharmaceutical Therapy Helsinki, 18-20 November 2018

### **DAY 1, SUNDAY, NOVEMBER 18, 2018**

- 13.00 – 18.30 REGISTRATION for ISRT 2018
- 14.00 – 16.00 SCIENTIFIC SESSION 1: NUCLEAR CARDIOLOGY**  
Moderators: Juhani Knuuti, Turku, Finland and Pietro Muto, Naples, Italy
- 14.00 – 14.30 O1 **Revolution in cardiac imaging: Quantitative perfusion, inflammation and hybrid imaging** Juhani Knuuti, Turku, Finland
- 14.30 – 15.00 O4 **Novel therapies of cardiac regeneration. How imaging can help in diagnosis, targeting and monitoring?** Seppo Ylä-Herttuala, Kuopio, Finland
- 15.00 – 15.30 O2 **Imaging innervation. Finally clinical applications?** Albert Flotats, Barcelona, Spain
- 15.30 – 16.00 O3 **Gauging cardiac repair, regeneration and inflammation with new molecular probes** James Thackeray, Hannover, Germany
- 16.00 – 16.30 **COFFEE & TEA BREAK**
- 16.30 – 18.45 SCIENTIFIC SESSION 2: NEW TRENDS IN ONCOLOGY AND PRECISION MEDICINE.**  
Moderators: **Vivek Subbiah**, MDACC, Houston, TX, USA and **Homer Macapinlac**, MDACC, Houston, TX, USA
- 16.30 – 16.55 O5 **Personalized medicine and precision oncology**, Vivek Subbiah, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center
- 16.55 – 17.20 O6 **Precision oncology in rare tumors: adopting the orphans**, Roman Groisberg, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- 17.20 – 17.45 O7 **Optimizing patient selection for phase 1 clinical trials: lessons from targeted therapy and immunotherapy drug development**, Shiraj Sen, Drug Development, Sarah Cannon Research Institute at HealthOne; Denver, CO, USA

17.45 – 18.20 O8      **Target discovery for precision oncology using large public databases**, Jason Roszik, Department of Genomic Medicine, UT MD Anderson Cancer Center

18.20 – 18.45 O12      **Re-188 Lipiodol Liver Cancer Project – an update on current status**, Ajit Shinto, Coimbatore, India

**WARMTH CONGRESS DINNER 1**

19.30 – 22.30      Restaurant Meripaviljonki

**DAY 2, MONDAY, NOVEMBER 19, 2018**

08.00 – 18.00      REGISTRATION for ISRT 2018

**09.00 – 11.00      OPENING CEREMONY**

Welcome Address      Partha Choudhury, President-Elect, WARMTH

Opening Remarks      Kalevi Kairemo, Congress President, ISRT-2018, WARMTH

Welcome Address      Pirkko Mattila, Minister of Health, Finland

WARMTH Candle Lighting Ceremony      WARMTH Board Members

AJIT PADHY ORATION      Steven M. Larson, MSKCC, NY, USA

*O10*      **“New Insights in Theragnostics”**

presenter      Andrew M. Scott, Melbourne, Australia

**11.00 – 11.30      COFFEE & TEA BREAK**

**11.30 – 13.00      SCIENTIFIC SESSION 3: RADIOEMBOLISATION AND LIVER THERAPIES**

Moderators: Patrick Flamen, Brussels, Belgium and Aviral Singh, Bad Berka, Germany

11.30 – 11.55 O11 **Personalized SIRT based on predictive dosimetry, regional functional reserve measurement and molecular imaging**, Patrick Flamen, Jules Bordet Institute, Brussels, Belgium

11.55 – 12.20 O9 **Oncolytic viruses**, Akseli Hemminki, University of Helsinki

12.20 – 12.40 O13 **Biologic dosimetry in SIRT**, Katherine Vallis, University of Oxford, UK

12.40 – 13.00 O14 **Intra-arterial PRRT of SSTR-expressing liver tumors**, Aviral Singh, Bad Berka, Germany

**Posters:** P1 ***The quantitative analysis of post-selective internal radiation therapy (SIRT) <sup>90</sup>Y microspheres PET/CT in hepatocellular carcinoma in comparison with <sup>99m</sup>Tc-labelled macroaggregated albumin (MAA) planar and SPECT/CT***, Ngoc Ha Le, Tran Hung Dao Hospital, Ho Chi Minh City, Vietnam

**13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI**

**14.00 – 16.00 SCIENTIFIC SESSION 4: NEW RADIONUCLIDE THERAPIES / RADIATION HAZARDS/ SAFETY ISSUES**  
Moderators: Seigo Kinuya, Kanazawa, Japan and Kazuko Ohno, Fukushima, Japan

14.00 – 14.30 O15 **Boron neutron capture therapy and world's first accelerator-based BNCT facility at Southern Tohoku General Hospital**, Yoshihiro Takai, Southern Tohoku BNCT Research Center, Japan

14.30 – 15.00 O16 **What did we learn from the Fukushima accident?** Ohtsura Niwa, Radiation Effects Research Foundation, Hiroshima/ Nagasaki, Japan

15.00 – 15.30 O17 **Regulatory nuclear safety aspects, Linear No-Threshold Hypothesis of risk from low-level radiation exposure**, Bennett S Greenspan, Society of Nuclear Medicine and Molecular Imaging, USA

**PANEL-discussion: Regulatory/ nuclear safety aspects**

Moderators: Seigo Kinuya, Kazuko Ohno and Bennet S Greenspan

Posters: P2 ***Establishment of incident reporting programme and lesson learnt in unsealed radionuclide therapy***, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan

- P3 ***Practices across Pakistan how medical emergency is handled in case of patients who has undergone unsealed radionuclide therapy***, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan
- 16.00 – 16.30 COFFEE & TEA BREAK**
- 16.30 – 18.15 SCIENTIFIC SESSION 5: PROSTATE CANCER: PSMA RADIOLIGAND THERAPY (PRLT) – WHAT DO WE KNOW AND WHAT IS NEW?**  
Moderator: Richard P. Baum, Bad Berka, Germany
- 16.30 – 16.45 O18 **Introduction to PRLT**, Richard P. Baum
- 16.45 – 17.00 O19 **Dosimetry following Lu-177 PSMA radioligand therapy and an insight into novel radionuclides for theranostics of prostate cancer**, Aviral Singh, Bad Berka, Germany
- 17.00 – 17.15 O20 **Dosimetry in PSMA radioligand therapy of metastasized prostate cancer using Lu-177 PSMA I&T and Lu-177 PSMA-617**  
Christiane Schuchardt, Bad Berka, Germany
- 17.15 – 17.45 O21 **PSMA targeting and therapy trials in Australia**, Andrew M. Scott, Melbourne, Australia
- 17.45 – 18.00 O22 **Ac-225- and Bi-213- PSMA-617 radioligand therapy in patients with castration resistant prostate cancer**, Mike Sathekge, Pretoria, South Africa
- 18.00 – 18.15 O23 **[<sup>18</sup>F]AIF-PSMA-HBED-CC and <sup>177</sup>Lu-PSMA-617 as a potential theragnostic tandem and comparison with <sup>68</sup>Ga-PSMA-HBED-CC in high-risk prostate cancer patients at initial staging**, Omar Alonso, CUDIM, Montevideo, Uruguay
- Posters: P4 ***<sup>177</sup>Lutetium-prostate-specific membrane antigen radionuclide treatment of lymph node metastatic prostate cancer with PSA recurrence: A cohort study***, Finn Edler von Eyben, Odense, Denmark
- P5 ***Dosimetry in Molecular Radiotherapy - Bad Berka Experience***,  
Christiane Schuchardt, Bad Berka, Germany
- P6 ***Web-Monitoring Tool for <sup>177</sup>Lutetium-PSMA Treatments in Prostate Cancer Patients***, Kalevi Kairemo, Helsinki, Finland

18.25 *Tram transportation to the City Hall in front of the Scandic Paasi hotel (Hakaniemi Square stop 0252)*

## **WARMTH CONGRESS DINNER 2**

19.00 – 20.30 **CITY HALL of Helsinki, Mayor Reception**

20.45 -21.45 *Tram transportation from the City Hall (Market Square stop) to the Scandic Paasi hotel (Hakaniemi Square) including sightseeing in Helsinki*

## **DAY 3, TUESDAY, NOVEMBER 20, 2018**

08.00 – 08.45 REGISTRATION for ISRT 2018

**8.45 – 11.00** **SCIENTIFIC SESSION 6: THYROID CANCER – QUO VADIS?**  
Moderators: Mark Tulchinsky, PA; USA & Raihan Hussain, Dhaka, Bangladesh

Debating Controversies in Radioiodine Imaging and Therapy of Thyroid Cancer

8.45 – 9.00 O24 **Introduction-thyroid cancer management,** Mark Tulchinsky, Hershey, PA, USA

9.00 – 9.15 O25 **Total vs. subtotal thyroidectomy. East, West , what´s the best?**  
Ilya V. Sleptsov, St. Petersburg, Russia

9.15 – 9.30 O26 **Dosimetric approach of thyroid cancer,** Henry Bom, Chonnam, South Korea

9.30 – 9.45 O27 **Management of I-131 refractory thyroid cancer: a multimodality approach,** Partha Choudhury, New Delhi, India

9.45 – 9.55 O28 **Prevalence of genetic duet and its influence on the prognosis of differentiated papillary thyroid carcinoma patients,** Sanjana Ballal, New Delhi, India

9.55 – 10.00 O29 **Comments -thyroid cancer management,** Raihan Hussain, Dhaka, Bangladesh

Panel discussion: Moderator Mark Tulchinsky

Panelists: Raihan Hussain, Henry Bom, Partha Choudhury and Ilya Sleptsov, St. Petersburg, Russia

- 10.05 – 10.30                    **"Radioiodine Imaging Before, After, Both or Neither ... and How?"**
- 10.30 – 10.55                    **"Controversies in Radioiodine Side-Effects: Confusion About Salivary Damage and Secondary Malignancy"**
- Posters:**    P7                    ***Antithyroglobulin antibody as a marker of successful ablation therapy in differentiated thyroid cancer***, Ayu Rosemeilia Dewi, Universitas Padjadjaran, Indonesia
- P8                    ***Importance of isolated raised thyroglobulin antibody in follow up and management of differentiated thyroid cancer***, Ray Soumendranath, Tata Medical Center, Kolkata, India
- P9                    ***Contribution of manual fusion in thyroid cancer whole body study with I-131. Case Report***, Mariela Agolti, Parana, Argentina
- P10                    ***Contribution of manual fusion in thyroid cancer whole body study with I-131***, Mariela Agolti, Parana, Argentina
- 11.00 – 11.10                    Lifetime Achievement Awards & Group Photo
- Irene Virgolini, President, WARMTH & Kalevi Kairemo
- 11.10 – 11.30                    COFFEE & TEA BREAK
- 11.30 – 13.00                    SCIENTIFIC SESSION 7: PEPTIDE RECEPTOR/ NEW THERAPIES**  
Moderator: **Irene Virgolini, Innsbruck, Austria**
- 11.30 – 11.45 O30                    **Value of FDG in NET: importance of dual tracer imaging**, Margarida Rodrigues Radischat, Innsbruck, Austria
- 11.45– 12.00 O31                    **Value of Re-PRRT in NET**, Anna Yordanova, Bonn, Germany
- 12.00– 12.15 O32                    **PRRT in G3-NEN**, Aviral Singh, Bad Berka, Germany
- 12.15– 12.35 O33                    **New peptides for PRRT in Non-NETs**, Irene Virgolini, Innsbruck, Austria
- 12.35– 12.50 O34                    **Long-term side effects and quality of life, patients view**  
Josh Mailman, San Francisco, USA

12.50– 12.58 O35 **A correlation between c-Fos expression and radioiodine in breast cancer cell lines**, Aisyah Elliyanti, Andalas University/ Dr.M.Djamil Hospital, Indonesia

**Posters:** P11 ***First ex-vivo experience with I- radiation and radioguided surgery technique in meningioma and neuroendocrine patients***, Chiara Maria Grana, European Institute of Oncology, Milan, Italy

P12 ***Lutetium-labelled DOTA-TOC and radionuclide therapy (PRRT) in China: First Experience***, Feng Wang, Nanjing, China

P13 ***Developing neuropeptide Y (NPY) nanoconstructs as potential theranostic agents***, Irfan Ullah Khan, Institute of Nuclear Medicine & Oncology, Lahore, Pakistan

**13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI**

**14.00 – 16.00 SCIENTIFIC SESSION 8: NEW ALPHA- THERAPIES**  
Moderators: Oyvind Bruland, Oslo, Norway and Roy Larsen, Oslo, Norway

14.00– 14.30 O36 **Predicting the future of Alpha: clinical indications and radioisotopes of choice?** Jean-Francois Chatal, Arronax, Nantes, France

14.30– 14.50 O37 **Radiometabolic therapy with <sup>223</sup>Ra-dichloride: the European Institute of Oncology experience**, Chiara Maria Grana, European Institute of Oncology, Milan, Italy

14.50– 15.10 O38 **Ra-223 in osteosarcoma –Ph I-trial**, Vivek Subbiah, MD Anderson Cancer Center, USA

15.10– 15.30 O39 **Ra-224 labelled biodegradable carbonate microparticles (Radspherin<sup>R</sup>) to combat microscopical residual peritoneal carcinomatosis**, Tina Bønsdorf, Oncoinvent AS, Oslo, Norway

15.30– 15.50 O40 **“Dual-alpha” - an expanding technology for development of targeted alpha therapies**, Asta Juzeniene, Norwegian Radium Hospital, Oslo, Norway

**Posters:** P14 ***Clinical case of benefit due to deviation in Ra-223 treatment schedule***, Tatiana Kochetova, MRRC, Obninsk, Russia

- P15 ***Personalized molecular imaging with bone scintigraphy, NaF-PET, and FDG-PET for evaluation of osteosarcoma response to Radium-223***, Kalevi Kairemo, Houston, TX, USA
- P16 ***Treatment response evaluation in soft-tissue osteosarcoma metastases using fluoride-18 (<sup>18</sup>F)-PET/CT radiomics analysis for <sup>223</sup>Ra-therapy***, Kalevi Kairemo, Houston, TX, USA
- P17 ***Substantiation of an individual therapeutic dose of <sup>153</sup>Sm-oxabiphor for the treatment of bone metastases***, Ganna Grushka, Grigorev Institute for Medical Radiology, Ukraine
- P18 ***Radionuclide therapy for bone pain palliation in anemic patients: role of erythropoietin***, Sukanta Barai, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- P19 ***<sup>18</sup>F-fluoroethyltyrosine PET/CT: the European Institute of Oncology experience in brain tumors***, Chiara Maria Grana, European Institute of Oncology, Milan, Italy
- P20 ***Pharmaceutical development of the therapeutic radiopharmaceutical based on  $\alpha$ -emitting Sm-153 in heat-sensitive carrier for brachytherapy of tumors of various locations***, NM Tolbit, Karpov Institute, Obninsk, Russia

#### **15.50 – 16.20 COFFEE & TEA BREAK**

**16.20 – 17.00** **SCIENTIFIC SESSION 9: FUTURE ASPECTS OF COLLABORATION OF WARMTH, IAEA AND WFNMB – ROUND TABLE DISCUSSION**  
Moderator: Irene Virgolini, Innsbruck, Austria

WARMTH perspective, Partha Choudhury, President-Elect

IAEA Perspective, NN, Vienna

WFNMB perspective, Andrew M. Scott, Melbourne, Australia

SNMMI perspective, Bennett Greenspan, USA

- O41 Presentation of ICRT 2019, Feng Wang, Nanjing, China
- O42 Closing remarks, Kalevi Kairemo